These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Strong crossreaction of human anti-aprotinin antibodies from heart transplant patient with [Arg15]aprotinin.
    Author: Brinkmann T, Körfer R, Wenzel HR, Tschesche H, Kleesiek K.
    Journal: Immunopharmacology; 1997 Jan; 35(3):221-8. PubMed ID: 9043935.
    Abstract:
    We detected anti-aprotinin antibodies by an enzyme immunoassay in serum of a 33 year old man who showed anaphylactic reactions during heart transplantation under aprotinin reexposition. The antibodies were isolated by affinity chromatography by aprotinin immobilized on CNBr activated Sepharose. The crossreactivity was tested by a competitive enzyme immunoassay (50% inhibition) against different aprotinin homologues and two human Kunitz-type protease inhibitors, bikunin and TFPI. In comparison with native aprotinin (immunoreactivity = 100%) the crossreaction of the homologue [Arg15]aprotinin was 76%, of [Val15]aprotinin 15% and of isoaprotinin 1, [Ala14,38]aprotinin and [seco15/16]aprotinin less than 10%. An immunoreactivity with bikunin and TFPI was not detected. Similar results were obtained with polyclonal anti-aprotinin antibodies from rabbit. Our results show that human anti-aprotinin antibodies are mainly directed against the reactive site of aprotinin. From this we conclude that the reactive site exposes the major epitope resulting in a major target site for antibodies in a species independent way, and therefore, it is obvious that the recombinant aprotinin homologue [Arg15]aprotinin, which is scheduled for therapy in open-heart surgery, will have similar immunogenic effects as native aprotinin.
    [Abstract] [Full Text] [Related] [New Search]